Top Page
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:EBR)
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) vs. iShares MSCI Australia ETF (EWA)
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 681.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -38.60M | -37.73M | -24.66M | -23.62M | ― | ― |
| Net Income | -44.81M | -20.17M | -35.04M | -33.09M | ― | ― |
Balance Sheet | ||||||
| Total Assets | 104.99M | 73.56M | 78.90M | 71.68M | 85.42M | 8.40M |
| Cash, Cash Equivalents and Short-Term Investments | 68.36M | 60.66M | 72.32M | 63.53M | 78.24M | 5.88M |
| Total Debt | 56.80M | 41.40M | 41.59M | 21.59M | 4.81M | 33.23M |
| Total Liabilities | 66.34M | 49.20M | 47.84M | 27.73M | 9.53M | 46.05M |
| Stockholders Equity | 38.65M | 24.36M | 31.06M | 43.95M | 75.90M | -37.65M |
Cash Flow | ||||||
| Free Cash Flow | -51.46M | -41.50M | -33.05M | -31.09M | -934.16K | -17.81K |
| Operating Cash Flow | -49.17M | -41.23M | -32.70M | -30.36M | -22.15K | -17.55K |
| Investing Cash Flow | -21.45M | 1.11M | -8.64M | -49.35M | -906.81K | -265.00 |
| Financing Cash Flow | 49.45M | 32.48M | 40.47M | 17.01M | 95.76M | 16.41K |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$24.72M | -2.93 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$33.22M | -7.32 | -58.27% | ― | -7.20% | 28.70% | |
44 Neutral | AU$330.69M | -4.19 | -134.69% | ― | ― | ― | |
44 Neutral | AU$164.04M | -15.03 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$54.46M | -4.24 | -128.19% | ― | -14.25% | -22.83% | |
37 Underperform | AU$13.97M | -0.99 | -1476.79% | ― | -2.82% | 32.47% |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
EBR Systems has called a 2026 Special Meeting of Stockholders to be held virtually on 12 March 2026 (AEDT), and has dispatched the Notice of Special Meeting and Proxy Statement, along with voting instruction forms for CHESS Depositary Interest holders and proxy cards for common stockholders. By facilitating electronic participation and voting for its globally dispersed investor base, the company is reinforcing stockholder engagement and governance processes as it advances development and potential commercialization of its wireless cardiac pacing technology.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.92 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems has called a virtual special meeting of stockholders for 12 March 2026, with the notice of meeting to be made available online around 28 January 2026, to consider changes affecting its capital structure. The company is proposing a consolidation of its common shares within a range of 5-for-1 to 20-for-1, while leaving ASX-listed CDIs unconsolidated and adjusting the CDI-to-common-share conversion ratio proportionately so that both the total number and trading price of EBR’s ASX CDIs remain unchanged, aiming to preserve relative value for CDI holders while potentially improving the profile and structure of its common equity.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems will convene a virtual special meeting of stockholders in March 2026 to vote on key corporate actions, including a proposed amendment to its charter to implement a reverse stock split within a 1-for-5 to 1-for-20 range, and the ratification and approval of a prior institutional placement completed in May 2025. The company emphasised that the consolidation will not change its total authorised share capital, the number of issued CHESS Depositary Interests, or the CDI price, with the main mechanical impact being a change in the CDI-to-share transmutation ratio. Communication to securityholders about the meeting will be dispatched in late January, and management will host an investor webinar ahead of the vote to explain the strategic rationale for the share consolidation, underlining EBR Systems’ effort to manage its capital structure while maintaining access to both U.S. and Australian markets.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems will present at the 44th Annual J.P. Morgan Healthcare Conference, where President and CEO John McCutcheon is set to brief investors on the company’s commercial progress, clinical programs and strategic priorities aimed at expanding adoption of its WiSE wireless cardiac pacing system. The company also disclosed that its estimated total addressable market has risen from US$3.6 billion to US$5.8 billion, reflecting the rapid expansion of the leadless pacemaker segment and higher expected average selling prices for the WiSE System, underscoring a significantly larger commercial opportunity for the business and its shareholders.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems reported strong commercial and clinical progress in the fourth quarter of FY2025, with WiSE System case volumes doubling from the prior quarter to 18 commercial implants and total commercial and pilot implants reaching 30. The company expects to post a sharp step-up in quarterly revenue to between US$870,000 and US$935,000, driven by growing adoption under its Limited Market Release, which now includes 9 additional purchase agreements and a total of 33 trained implanting physicians, while expanding hospital readiness and reimbursement processes for the WiSE technology.
Clinically, EBR advanced two key studies that underpin its long-term growth strategy: the WiSE-UP post-approval study began enrolling patients to generate real-world performance and outcomes data across more than 300 heart failure patients over five years, and the TLC-AU feasibility study enrolled its first patient to evaluate totally leadless CRT in both upgrade and de novo candidates, potentially opening up roughly three-quarters of the CRT market to WiSE as a first-line option. The company also intensified its investor outreach through multiple healthcare and small/mid-cap conferences and roadshows, reinforcing its profile with the investment community as it builds the evidence base and commercial infrastructure needed for broader market adoption of its wireless pacing platform.
The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.87 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has announced the cessation of 170,480 securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This announcement, made on December 15, 2025, reflects a change in the company’s issued capital and could impact stakeholders’ perception of the company’s financial strategies and market positioning.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. announced the first patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study, marking a significant milestone in the development of its WiSE System as a first-line therapy for heart failure patients. This study, conducted in Australia, aims to evaluate the feasibility of using the WiSE System with a leadless pacemaker to provide a totally leadless CRT solution, potentially expanding EBR’s addressable market and reinforcing its leadership in heart-failure treatment.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems Inc. announced the issuance of 207,000 unquoted equity securities as part of an employee incentive scheme. This move is likely aimed at retaining and motivating employees by providing them with a stake in the company’s future success, potentially impacting the company’s operational dynamics and aligning employee interests with those of the shareholders.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has announced the expansion of its intellectual property portfolio with the granting of four new patents, three from the US Patent and Trademark Office and one from the Japan Patent Office. This development enhances the protection of its WiSE technology, the world’s only wireless cardiac pacing device for heart failure, and extends the patent runway for its innovations. However, the company has received a preliminary disallowance notice from the USPTO regarding a patent term extension application, which it is currently addressing. The continued growth of EBR’s patent portfolio underscores its commitment to research and development, potentially strengthening its market position and creating barriers for competitors.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company is set to quote 117,303 securities under the ASX code EBR, with the issue date being December 1, 2025. This move is part of the company’s strategy to enhance its market presence and potentially attract more investors. The announcement signifies a step forward in EBR Systems’ efforts to expand its financial operations and strengthen its position in the market.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has released a presentation providing general information about its activities and financial status. The document emphasizes the company’s compliance with regulatory requirements and highlights that its CHESS Depositary Interests are traded on the ASX. The release serves as an informational update rather than a financial advisory, indicating that stakeholders should seek independent advice for investment decisions.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. announced its participation in the Bell Potter Healthcare Conference 2025, where management will present their pioneering wireless cardiac pacing technology. This virtual event provides a platform for EBR Systems to showcase its WiSE technology, which could significantly impact the cardiac pacing industry by offering a more anatomically correct and less invasive solution for heart failure patients. The conference presentation is an opportunity for EBR Systems to strengthen its industry positioning and engage with stakeholders about its innovative approach to cardiac rhythm management.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.86 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. announced the cessation of certain securities, specifically 309,278 warrants and 69,105 options, due to their expiration without exercise or conversion as of November 3, 2025. This development may impact the company’s capital structure and could influence investor perceptions and market positioning.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. announced significant progress in Q3 2025, securing CMS approval for both NTAP and TPT reimbursement for its WiSE CRT System, effective October 2025. This approval establishes a comprehensive Medicare reimbursement pathway, enhancing the system’s adoption in both inpatient and outpatient settings. The company reported a 201% increase in revenue from Q2 to Q3 2025, driven by a tripling of case volumes and successful pilot launches. EBR also advanced its Limited Market Release preparations, signing additional purchasing agreements and training physicians, which aligns with the commencement of U.S. Medicare reimbursement programs. These developments are expected to accelerate the adoption and operational processes of the WiSE CRT System, positioning EBR for further growth.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has announced the issuance of 357,000 unquoted equity securities under an employee incentive scheme, which are not intended to be listed on the ASX. This move is part of the company’s strategy to motivate and retain its workforce, potentially impacting its operational efficiency and market competitiveness positively.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has announced the application for quotation of new securities on the Australian Securities Exchange (ASX). The company plans to quote 30,208 new securities under the code EBR CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB, with an issue date of November 3, 2025. This move could potentially enhance the company’s market presence and provide additional liquidity options for stakeholders.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems, Inc. has announced the enrollment of the first two patients in its WiSE-UP post-approval study, which aims to collect real-world evidence on the effectiveness of the WiSE left ventricular endocardial pacing system for cardiac resynchronization therapy. This significant milestone involves tracking over 300 patients across 50 US centers over five years, providing valuable insights into both short- and long-term outcomes. The study is expected to enhance the understanding of CRT applications and improve standards of care for heart failure patients, thereby strengthening EBR Systems’ position in the cardiac rhythm management industry.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
EBR Systems announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, highlighting its innovative WiSE technology. This participation underscores EBR’s commitment to advancing cardiac pacing solutions and may enhance its visibility and positioning in the medical technology industry.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.